NCT04605185View on ClinicalTrials.gov

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Donafenib Tosilate Tablets

100mg Qd/150mg Qd/100mg Bid, po

BIOLOGICAL

Toripalimab Injection

240 mg, iv drip,q3w

Trial Locations (1)

410006

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04605185 - Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter